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ABSTRACT: In December 2019, a novel coronavirus was 
discovered and associated with a cluster of pneumonia of 
unknown cause in China. SARS-CoV-2 rapidly spread and is 
now characterized as a pandemic. The objective of this study is 
to discuss COVID-19 general features, including epidemiology, 
transmission, control measures, virology, diagnosis, clinical 
characteristics and radiological and laboratory results. In this 
context, literature was assessed to compare the three most 
affected countries in Asia, Europe and Americas on March 
31, 2020. The main form of transmission is human-to-human 
by respiratory secretions, and studies indicated substantial 
involvement of asymptomatic patients in this process. COVID-19 
patients are predominantly men and may present multiple 
symptoms, especially fever and cough. Arterial hypertension and 
diabetes mellitus were the most common comorbidities. Worse 
outcomes are associated with increased age, comorbidities, 
and complications. Abnormalities in computed tomography of 
the chest are frequent, with pulmonary ground-glass opacity 
and bilateral patchy shadowing as the most common patterns, 
but a significant percentage of patients do not present any 
findings at time of admission. Laboratory results often present 
lymphocytopenia, increased neutrophils and platelet counts, 
erythrocyte sedimentation rate, lactate dehydrogenase, C-reactive 
protein, ferritin, total bilirubin, aspartate aminotransferase, 
alanine aminotransferase, creatinine, creatine phosphokinase, 
myoglobin, glucose and cytokines. Although radiological findings 
and laboratory results presented similarities in China, Italy and 
USA, case-fatality rates can be conflicting suggesting, therefore, 
the need for studies according to each region. 
Keywords: Coronavirus infections; Epidemiology; Signs and 
symptoms; Pandemics.
RESUMO: Em dezembro de 2019, um novo coronavírus foi 
identificado e associado à ocorrência de pneumonia de causa 
desconhecida na China. SARS-CoV-2 rapidamente disseminou-
se, e, atualmente, a COVID-19 é classificada como pandemia. 
O objetivo desse estudo consiste em discutir as características 
gerais da COVID-19, incluindo a epidemiologia, transmissão, 
medidas de controle, virologia, diagnóstico, apresentações 
clínicas e achados radiológicos e laboratoriais. Nesse contexto, 
foram consultados artigos publicados em base de dados com a 
finalidade de comparação entre países mais afetados na Ásia, 
Europa e América até 31 de março de 2020. A principal forma 
de transmissão ocorre entre humanos por secreções respiratórias, 
e estudos indicam um substancial envolvimento de pacientes 
assintomáticos nesse processo. Pacientes com COVID-19 são 
predominantemente homens e podem apresentar inúmeros 
sintomas, especialmente febre e tosse. Hipertensão arterial e 
diabetes mellitus foram as comorbidades mais comuns. Pior 
prognóstico está associados a aumento da idade, comorbidades 
e complicações. Anormalidades na tomografia computadorizada 
de tórax são frequentes, sendo opacidades em vidro fosco e 
infiltrados bilaterais os padrões pulmonares mais comuns, contudo 
porcentagem significativa dos pacientes não apresenta alterações 
na admissão. Exames laboratoriais normalmente apresentam 
linfocitopenia, aumento de contagem de neutrófilos e plaquetas, 
velocidade de hemossedimentação, lactato desidrogenase, proteína 
C reativa, ferritina, bilirrubina total, aspartato aminotransferase, 
alanina aminotransferase, creatinina, creatina fosfoquinase, 
mioglobina, glicose e citocinas. Apesar dos achados radiológicos 
e laboratoriais apresentarem similaridades na China, Itália e 
EUA, as taxas de mortalidade podem ser conflitantes, sugerindo, 
portanto, a necessidade de estudos de acordo com cada região..
Palavras-chave: Infecções por Coronavírus; Epidemiologia; 
Sinais e sintomas; Pandemia.
163
Rangel AR, et al. COVID-19 in China, Italy and the United States of America: a short review
INTRODUCTION
In December 2019, there were several reports about patients with acute respiratory infection 
of unknown cause in hospitals of Wuhan, China1-3. 
The pathogen was identified as a new coronavirus and 
first named as 2019-nCoV1,2. In February 2020, the 
Coronavirus Study Group (CSG) of the International 
Committee officially named the virus as Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)1. The 
coronavirus-related disease was named COVID-19 by the 
World Health Organization (WHO)4.
In this review article, we intend to discuss 
COVID-19 general features, including epidemiology, 
transmission, control measures, virology, diagnosis, clinical 
characteristics and radiological and laboratory results. 
Thus, literature was assessed to summarize similarities and 
differences between the three most affected countries in 
Asia, Europe and Americas on March 31, 2020, according 
to the WHO 71st report5.
DISCUSSION
Epidemiology
The first cases of the disease were linked to a 
seafood market in Wuhan, province of Hubei, China, in 
which the majority of the patients had been there or stayed 
nearby before getting sick1,2, suggesting that the origin of 
the virus was from the market; although, this hypothesis 
was not confirmed so far1.
The number of cases rapidly increased and spread 
to other locations inside and outside China2. On January 
30, 2020, WHO declared the COVID-19 outbreak a public 
health emergency of international concern (PHEIC)6, and on 
March 11, 2020 characterized the disease as a pandemic7.
According to data of WHO on May 5, 2020, 
COVID-19 was present in every continent, except in 
Antarctic, with 3,525,116 confirmed cases and 243,540 
deaths8. The United States of America (USA) was the 
country with more confirmed cases worldwide, accounting 
nearly 78% of the cases in the Americas; when comparing 
continents, Europe had the higher number, with almost 
44% of the total amount8.
Transmission
The main form of transmission of COVID-19 is 
human-to-human by respiratory secretions, with droplets 
or contact9,10. Wang et al.11 evaluated the presence of 
SARS-CoV-2 in other sites, including nasal samples, 
sputum, pharyngeal swabs, bronchoalveolar lavage fluid, 
fibrobronchoscope brush biopsy, blood, urine, and feces. 
In this analysis, besides urine samples, all the other sites 
had a percentage of positive results (Table 1).
Table 1: Study of Wang et al. evaluating the presence of SARS-
CoV-2 in 1070 specimens of 205 patients with COVID-19













Other  s tudy ident i f ied  SARS-CoV-2 in 
gastrointestinal tract, saliva, and urine, suggesting potential 
routes of transmission12. COVID-19 may also have a 
systemic component, supported by the presence of viral 
RNA in the blood of some patients10,11. These findings 
endorse the possibility that testing of specimens from 
multiple locations may reduce the risk of false-negative 
results11. However, there is not enough data for decisive 
conclusions, reaffirming that more studies are needed to 
fully understand the forms of transmission of the novel 
coronavirus. 
Moreover, the period during the illness that an 
infected patient can transmit the disease is uncertain, but 
it can start before the development of symptoms10,13.
Arons et al.14 evaluated an outbreak of COVID-19 
in a nursing facility in the USA, where 56% of patients 
with SARS-CoV-2 infection reported no symptoms at 
the moment of the test. Of those asymptomatic patients, 
86% developed symptoms later, being classified as 
presymptomatic patients. It is suggested that asymptomatic 
and presymptomatic patients had a contribution to the 
extent of the spread of COVID-19 in this facility, with a 
potential of viral shedding.
On top of that, studies have shown high viral load in 
the beginning of the symptomatic phase, suggesting more 
risk of transmission in this stage15. Similar values were found 
in symptomatic and asymptomatic patients, reasserting the 
transmission of the disease by asymptomatic patients15. 
Therefore, evidence of SARS-CoV-2 transmission from 
presymptomatic individuals has been shown in other 
investigations14,16-18.
Control measures 
WHO suggested some measures to control the 
transmission of the virus, such as rapid case identification, 
rapid testing and isolation of cases, comprehensive contact 
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tracing and quarantine of contacts19. These actions may 
reduce the spread of COVID-19, avoiding the health 
systems overload and allowing them to efficiently take 
care of the demand.
Several countries, which had a large number of 
community transmission, implemented other measures to 
contain the outbreak, for example, widespread population-
level physical distancing measures and movement 
restrictions19. However, these actions significantly 
impact the society, causing innumerous psychological 
consequences20,21 and negative impacts in economy19,22. 
Moreover, some groups can be more affected, such as 
people in poverty, immigrants, refugees and those who live 
in overcrowded and under-resourced settings19,23.
Virology
SARS-CoV-2 is a single-stranded positive RNA 
virus that belong to the Coronaviridae family, which 
can infect humans and animals, causing respiratory, 
gastrointestinal diseases, and other affections2,24.
Besides the recently discovered SARS-CoV-2, there 
are six known coronavirus that infect humans: HCoVs-
NL63, HCoVs-229E, HCoVs-OC43, HCoVs-HKU1, 
severe acute respiratory syndrome coronavirus (SARS-
CoV) and Middle East respiratory syndrome coronavirus 
(MERS-CoV)1-3,24. The majority of them causes mild 
diseases, but two were responsible for thousands of deaths 
in the twenty first century, SARS-CoV, which caused severe 
acute respiratory syndrome outbreak in 2002, especially 
in Asia, and the MERS-CoV, which caused Middle East 
respiratory syndrome outbreak in 20123,24,25.
SARS-CoV-2 is a beta coronavirus, as SARS-CoV 
and MERS-CoV, but it is considered to be more infectious 
than them, because it has a higher transmissibility9. Studies 
demonstrated that SARS-CoV-2 uses the same receptor as 
SARS-CoV to enter host’s cells, the angiotensin-converting 
enzyme 2 (ACE2), different from MERS-CoV, which uses 
the dipeptidyl peptidase 4 (DPP4)1,26-28 (Table 2).
Table 2 - Comparison between SARS-CoV-2, SARS-CoV and MERS-CoV.
MERS-CoV SARS-CoV SARS-CoV-2
Similarity with SARS-CoV-2 51,8% 79,0% -
Target receptor in human’s cells DPP4 ACE2 ACE2
ACE2: angiotensin-converting enzyme 2; DPP4: dipeptidyl peptidase 4 
Furthermore, many studies were made to elucidate 
the distribution of ACE2 through the body, aiming to 
identify which cells might represent a way of entrance for 
SARS-CoV-24,29. High expression of this receptor was found 
in type II alveolar cells (AT2) of the lung, upper esophagus 
and stratified epithelial cells, absorptive enterocytes from 
ileum and colon, cholangiocytes, myocardial cells, kidney 
proximal tubule cells, and bladder urothelial cells4,29. These 
findings support the idea that other organs might be at risk 
of infection by the SARS-CoV-2. 
Genetically, SARS-CoV-2 is more similar to 
coronavirus of bat origin: bat-SL-CoVZC45 and bat-SL-
CoVZXC214,25. In fact, in nucleotide identity, it has 79.0% 
of similarity to SARS-CoV, 51.8% with MERS-CoV, and 
over 90% to a bat coronavirus24. These findings suggest 
that SARS-CoV-2 might be originated from bats, which 
are a natural reservoir of many coronavirus1,28, and could be 
transmitted to human directly from them or by an unknown 
intermediate1,2. 
Evaluation and Diagnosis
As a new disease that presents flu-like symptoms, 
which lead to many possible differential diagnoses, the 
suspicion can occur in three possible scenarios30. The first 
is a person presenting acute respiratory disease, with fever 
and symptoms of respiratory disease, such as shortness 
of breath and cough, and with a history of travel to or 
residence in areas with reported community transmission 
within 14 days of the beginning of symptoms30. The second 
is a symptomatic individual presenting acute respiratory 
illness with a history of contact with a suspect or confirmed 
case within 14 days of the beginning of symptoms30. The 
third is a patient presenting severe respiratory illness, 
with fever and symptoms of respiratory disease, requiring 
hospitalization and without other diagnosis that explain 
all the findings30. These cases are labeled as suspect and 
require laboratory confirmation of SARS-CoV-2 infection. 
The confirmed diagnosis is made by nucleic acid 
amplification tests (NAAT), such as real-time reverse-
transcription polymerase chain reaction (rRT-PCR), based 
in the detection of parts of the viral RNA31. The chosen 
samples are respiratory secretions, especially from the 
upper respiratory tract for initial testing31,32. The Centers 
for Disease Control and Prevention (CDC) of the USA 
recommends nasopharyngeal, oropharyngeal specimen, 
nasal swab specimen, nasopharyngeal wash/aspirate 
or nasal wash/aspirate specimen32. The test of lower 
respiratory tract also can be done31,32.
As a matter of fact, because COVID-19 is a new 
disease, most laboratories were not prepared to deal with 
the high number of cases that need to be evaluated33. So, 
in order to test the patients that are more likely to have the 
disease, some criteria can be established, such as prioritize 
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individuals with more severe illness and contact with 
confirmed cases33,34.
Clinical characteristics
First, in January 2020, Huang et al.35 reported the 
main clinical features of 41 SARS-CoV-2 infected patients 
in Wuhan, observing male prevalence (73%) and a median 
age of 49 years (IQR, 41-58). Subsequent studies conducted 
in the same hospital presented similar features36,37.
In February 2020, also at the epicenter of the 
COVID-19 pandemic, 138 patients presented similar 
results, with a prevalence of men (54.3%) and a median 
age of 56 years (IQR, 42-68)38.
Guan et al.12, in a larger study, with data regarding 
1099 patients from 30 provinces in China, also showed 
a preponderance of men (58%) and a median age of 47 
years (35-58).
In Italy, a retrospective case series of 1591 patients 
with COVID-19 referred for Intensive Care Unit (ICU) 
admission, where 82% were male and the median age was 
elevated [63 years (IQR, 56-70) years]39, which is possibly 
associated with demographic characteristics in this country. 
Similarly, in the USA, a multicenter retrospective 
analysis in Seattle also presented that 63% of patients were 
men and had a mean age of 64 years40.
Clinical Features
The median time from onset of symptoms to first 
hospital admission was seven days35,38. Almost 90% of 
patients infected with SARS-CoV-2 presented multiple 
symptoms37. Initial studies about clinical manifestations of 
the disease included fever as the most common symptom 
(83-98.6%), followed by cough (59.4-82%) and fatigue/
myalgia (38.1%-69.6%), resembling SARS-CoV and 
MERS-CoV infections12,35-37.
Guan et al.12, however, suggested that fever was 
not the hallmark of COVID-19 onset, since it was present 
in only 43.8% of the patients at the time of admission, but 
88.7% of the patients developed during hospitalization. 
Gastrointestinal symptoms were uncommon and 
included nausea and vomiting (1-5%), and diarrhoea 
(2-3.8%). When analyzing only critically ill patients, the 
prevalence of those symptoms increased to 10.1%38 (Table 
3).
Table 3 – Summary of Clinical Manifestations in COVID-19 patients in China, Italy and United States of America
Huang et al. Yang et al. Chen et al. Wang et al. Guan et al. Arentz et al.
n=41 n=52 n=99 n=138 n=1099 n=21
Fever 98.6% 98% 83% 98% 43.8% 52.4%
Cough 76% 77% 82% 59.4% 67.8% 47.6%
Fatigue 44% - - 69.6% 38.1% -
Diarrhoea 3% - 2% 10.1% 3.8% -
Nausea/Vomiting 5% 4% 1% 10.1% 5% -
Comorbidities 
The presence of any comorbidity varied from 
23.7% to 46.7% according to studies in China12,38. Arterial 
hypertension, cardiovascular disease, and diabetes mellitus 
were the most common comorbidities associated with 
COVID-197,12,35-38,40-42.
Furthermore, studies showed a higher prevalence 
of underlying diseases in Italy (86%) and USA (37.6-
86%)39,41,43. Moreover, an analysis of critically ill patients in 
Washington, USA, reported that almost half of the patients 
had chronic kidney disease (CKD) (47.6%) and congestive 
heart failure (42.9%)41 (Table 4).
Table 4 - Summary of Comorbidities in COVID-19 Patients in China, Italy and United States of America
 Huang et al. Yang et al. Chen et al. Wang et al. Guan et al. Onder et al. Grasselli et al. Arentz et al.
 n=41 n=52 n=99 n=138 n=1099 n=355 n=1591 n=21
Coexisting disorder 32% 40% 51% 46.4% 23.7% 99.2%- 68% 86%
Arterial hypertension 15% - - 31.2% 15% - 49% -
Diabetes mellitus 20% 17% 12% 10.1% 7.4% 35.5% 17% 33.3%
Cardiovascular diseasea,b,c 15% 10% 40% 14.5% 2.5% 54,5%- 21% 42.9%
COPD 2% 8% - 2.9% 1.1% - 4% 33.3%
Malignancy 2% 4% 1% 7.2% 0.9% 20.3% 8% -
Cerebrovascular disease - 13.5% - 5.1% 1.4% 9.6%- - -
CKD - - - 2.9% 0.7% - 3% 47.6%
COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease. a Cardiovascular and cerebrovascular diseases grouped (Chen et al.). b 
Cardiovascular disease included atrial fibrillation and ischemic heart disease (Onder et al.). c Congestive heart failure (Arentz et al.).
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Complications 
Acute respiratory distress syndrome (ARDS) was 
the main complication for COVID-19, suggesting a stronger 
component of respiratory affection, according to studies 
from Wuhan, China12,35-38. Additionally, the prevalence of 
acute cardiac injury, acute kidney injury (AKI), and liver 
disfunction revealed that other organ systems were also 
compromised12,35-38,41. 
Analysis of 1099 COVID-19 patients across 
China revealed that ARDS and AKI only occurred in 
3.5% and 0.5% of cases, respectively12. Differently, 
the analysis of severe COVID-19 patients presented an 
increased prevalence of ARDS (81%), AKI (29%), and 
a higher demand for medical ventilation (71%) and renal 
replacement therapy (RRT) (17%)36. 
In Washington, the first description of COVID-19 
critically ill patients in the USA, revealed that 95.2% of all 
the patients presented ARDS and that 71% of them required 
mechanical ventilation41.  Grasselli et al.39 presented 
compatible outcomes in Italy, revealing that 99% (95% 
CI, 98%-99%) of ICU patients needed respiratory support, 
including 88% (95% CI, 87%-90%) who received invasive 
mechanical ventilation (Table 5). 
Table 5 - Summary of Complications in COVID-19 Patients in China, Italy and United States of America
 Huang et al. Yang et al. Chen et al. Wang et al. Guan et al. Arentz et al. Grasseli et al.
 n=41 n=52 n=99 n=138 n=1099 n=21 n=1591
Pneumonia 100% - - - 91.1% - -
ARDS 29% 67% 17% 19.6% 3.4% 95.2% -
Invasive mechanical ventilation 10% 71% 4% 47.2% 6.1% 71% 88%
Acute cardiac injury; 
Cardiomyopathy 12% 23% - 7.2% - 33.3% -
AKI 7% 29% 3% 3.6% 0.5% 19.1% -
RRT 7% 17% 9% - 0.8% - -
Liver dysfunction - 29% - - - 14.3% -
ARDS: Acute respiratory distress syndrome; AKI: Acute kidney injury; RRT: renal replacement therapy.
a Defined as evidence of a globally decreased left ventricular systolic function on transthoracic echocardiogram in addition to clinical signs of cardiogenic 
shock, an elevation in level of creatinine kinase or troponin I, or a decrease in central venous oxygen saturation (Arentz et al.)
Risk factors for ICU admission
Initially, only the presence of complications was 
statically significant for admission to ICU35. Subsequent 
studies demonstrated that the elderly and patients with any 
underlying disease were prone to poor clinical outcomes 
and increased risk of death, correlating these findings with 
a weaker immune response and cytokine storm in those 
patients36-38.
Patients in ICU in Wuhan, China, were older 
[median age 66 years (IQR, 57-78) vs 51 years (IQR, 
37-62); p < 0.001] and more likely to have complications 
and chronic illness (72.2% vs 46.6%; p<0.001), including 
arterial hypertension (58.3% vs 21.6%), diabetes mellitus 
(22.2% vs 5.9%), cardiovascular disease (25.0% vs 10.8%), 
and cerebrovascular disease (16.7% vs 1.0%) than non-
ICU patients38. COVID-19 in Wuhan, China, also tended 
to progress faster in the elderly, with shorter days between 
the occurrence of the first symptoms until death among 
people aged 70 years or more than those aged less than 70 
years (11.5 vs 20 days, p=0.033)44.
In agreement, an Italian cohort referred that 68% of 
the ICU patients had at least one comorbidity. However, 
the median age of severe patients was 63 (IQR, 56-70) 
years, the same as the median age of all positive Italian 
cases with COVID-19, suggesting that older age alone is 
not a risk factor for admission to the ICU39. On this basis, 
USA studies also referred a higher percentage of chronic 
illness among patients requiring ICU45, and an increased 
risk of poor outcomes among people aged ≥85 years42,43.
In Wuhan, China, non-survivors were mostly 
men (66%), and 50% of them had chronic medical illness. 
Even more, these patients were more likely to receive 
mechanical ventilation (94% vs 35%), either invasively or 
non-invasively, when compared with survivors36. Likewise, 
in Italy, non-survivors were predominantly men (70%) and 
48.5% of them had 3 or more underlying diseases34.
Comparison of fatalities between China and Italy 
initially evidenced equivalent case fatality rates (2.3)46. 
Furthermore, the current difference between the overall 
case-fatality rate in Italy (7.2) and China (2.3) was 
suggested to be related with: demographic differences 
between those countries, including older patients with 
more comorbidities in Italy; the classification method 
of COVID-19-related deaths and different strategies for 
SARS-CoV-2 infection diagnosis34. In this context, Lippi 
et al.13 also suggested that the higher risk of death in Italy 
could be associated to the variable frequency of risk factors 
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across different populations. 
Radiological Findings 
Huang et al.35 revealed that all patients showed 
abnormalities in computed tomography (CT) of the chest at 
admission and 98% had bilateral pulmonary involvement, 
findings consistent with posterior studies also realized in 
Wuhan, China36-38. 
A larger study in China including 1099 patients 
revealed no CT abnormalities at the time of admission 
in 13.8% of them and absence of radiologic or CT 
abnormalities in 17.9% of those with no severe disease. 
Pulmonary ground-glass opacity (56.4%) and bilateral 
patchy shadowing (51.8%) were the most common 
patterns12.
An abnormal chest radiograph was observed in 20 
patients (95%) at admission in ICU patients in Washington, 
USA at admission. The most common findings on initial 
radiograph were bilateral reticular nodular opacities (11 
patients [52%]) and ground-glass opacities (10 [48%]). 
By 72 hours, 18 patients (86%) had bilateral reticular 
nodular opacities and 14 (67%) had evidence of ground-
glass opacities41.
In another retrospective study in Seattle, USA, 
almost equal results were observed. A chest radiograph 
was obtained in 23 patients (96%) on ICU admission, and 
all the radiographs showed bilateral pulmonary opacities40.
Laboratory Results
In China, lymphocytopenia (lymphocyte count 
<1.0×109/L) was present in 35%-83.2% of the patients1,12,35-38. 
In retrospective studies with critically ill adult patients, low 
lymphocyte count occurred in more than 80% of them, a 
feature that is also prominent in SARS-CoV and MERS-
CoV infection36. However, in other studies, only 35% of 
non-severe COVID-19 patients had lymphocytopenia, 
suggesting that a lower lymphocyte count reflects the 
severity of SARS-CoV-2 infection37. In the USA, Bhatraju 
et al.40 exhibited common lymphocytopenia (75%) among 
patients admitted to ICU, and Arendtz et al. 41 presented that 
67% of the ICU admitted patients had absolute lymphocyte 
count of less than 1000 cells/μL.
In China, the blood counts of patients on admission 
showed that 25%-33.7% had leukopenia (white blood cell 
count <4.0×109/L)12,35. In USA, Arentz et al.41 presented 
that 67% of the patients had white blood cell count in the 
normal range.
Lactate dehydrogenase was increased in 39.9% 
to 75% of the patients37,38. D-dimer, C-reactive protein, 
aspartate aminotransferase, and interleukin (IL)-6 were also 
elevated in plasma (36%, 86%, 34%, 52%, respectively)37. 
Other findings included decreased albumin and increased 
levels of neutrophils, platelets, erythrocyte sedimentation 
rate, total bilirubin, alanine aminotransferase, ferritin, 
creatinine, creatine kinase, myoglobin and glucose12,35,37.
There were also differences in laboratory findings 
between patients that required ICU and those who not. ICU 
patients presented higher white blood cell and neutrophil 
counts, as well as higher levels of D-dimer and creatine 
kinase than those not admitted to the ICU38.
Immune response and Cytokine Storm
The spread of SARS-CoV-2 particles through 
the respiratory mucosa infects other cells and triggers 
immune responses, inducing a systemic cytokine storm 
that generates changes in peripheral white blood cells or 
immune cells. At the same time that the immunological 
response is vital for the control and resolution of infections, 
it can also lead to immunopathogenesis when out of 
control1,38.
COVID-19 patients had increased levels of plasma 
cytokines and chemokines, including IL-1, IL-2, IL-4, IL-7, 
IL-10, IL-12, IL-13, IL-17, granulocyte colony-stimulating 
factor (GCSF), macrophage colony-stimulating factor 
(MCSF), 10kD interferon-gamma-induced protein (IP-10), 
monocyte chemoattractant protein-1(MCP-1), macrophage 
inflammatory protein 1-α (MIP-1α), hepatocyte growth 
factor (HGF), interferon gamma (IFN-γ) and tumor necrosis 
factor α (TNF-α)1. 
Cytokines in plasma were elevated in individuals 
infected by SARS-CoV-2 that required ICU admission, 
suggesting an association with COVID-19 severity. 
Neutrophil count, D-dimer, blood urea nitrogen (BUN), 
and creatinine levels were significantly higher in severe 
patients, while the lymphocyte counts were decreased. 
Inflammatory factors IL-2, IL-6, IL-7, IL-10, and TNF-α 
were also elevated1,35.
Lymphocytopenia was higher in ICU patients (85% 
vs 54%, p <0.045) when compared with non-ICU patients35. 
Some studies suggested that a substantial decrease in the 
total number of lymphocytes indicates that coronavirus 
induces the consume of many immune cells and inhibition 
of the body’s cellular immune function. Thus, damage to 
T lymphocytes might be an important factor leading to 
exacerbations of patients37.
Moreover, strengthening of immune support could 
be beneficial to populations with low immune function 
with COVID-19, such as the elderly, diabetics, people 
with long-term use of immunosuppressive agents, and 
pregnant women37.
CONCLUSION
SARS-CoV-2 is a coronavirus that emerged in 
China. The infection is now a pandemic that rapidly spread 
throughout the world and led to a global effort to contain it. 
Studies suggested that asymptomatic patients contributed 
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to the extent of the spread of the disease. COVID-19 
predominantly affects men and may present with multiple 
symptoms. COVID-19 worse outcomes are associated 
with increased age, comorbidities, complications, 
lymphocytopenia, and cytokine storm. Clinical features, 
radiological findings and laboratory results presented 
similarities in different populations, but case-fatality 
rates can be conflicting, exposing the necessity of studies 
according to each region.
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